Biopharma firm Gilead announces lenacapavir licensing for HIV treatment

“The licencing agreements enabling generic versions of the HIV prevention drug, lenacapavir, successful definite countries is an important measurement forward, but ample parts of the satellite stay excluded, including countries wherever trials were conducted,” IAS president Beatriz Grinsztejn said successful a connection issued connected Thursday.

“We are hopeful that the velocity with which these agreements were reached volition beryllium maintained, and that the remainder of the satellite volition soon payment from akin agreements to marque lenacapavir much affordable and connection a further potent enactment successful the HIV prevention toolbox,” Dr I S Gilada, president emeritus, AIDS Society of India and governing assembly subordinate of International AIDS Society, added.

Three of the generic manufacturers person their operations successful India, 1 successful Egypt, 1 successful Pakistan and 1 successful the US. Gilead added that the agreements were signed “in beforehand of immoderate planetary regulatory submissions to alteration these countries to rapidly present generic versions of lenacapavir for HIV prevention” erstwhile they person regulatory approval.

This volition substantially trim the clip to market. However, galore countries with precocious HIV incidence are not included successful the licensing arrangements, which volition dilatory access.Six-monthly injections of lenacapavir showed 100% extortion against HIV acquisition among much than 5,000 cisgender women successful South Africa and Uganda successful the Phase 3 PURPOSE-1 proceedings presented astatine AIDS 2024, the 25th International AIDS Conference.

The results of the PURPOSE -2 proceedings released successful September 2024, showed that 99.9% of the 2,180 cisgender men and gender-diverse participants successful the United States, South Africa, Peru, Brazil, Argentina, Mexico, and Thailand who received the injection did not get HIV.

New information are owed to beryllium released astatine HIVR4P 2024,the 5th HIV Research for Prevention Conference, taking spot connected 6-10 October 2024.
The IAS calls connected stakeholders to enactment radical archetypal and guarantee accelerated and equitable entree to lenacapavir for each those successful need.